Biotage AB announced its strategic collaboration with Shandong Yingsheng Biotechnology Co., Ltd.. Yingsheng is mainly focused on independently researching, producing and selling in vitro diagnostic reagents and medical equipment, building a genetic detection platform and mass spectrometry detection platform around metabolomics and genetics. Biotage and Yingsheng have now agreed to develop Clinical Mass Spectrometry Applications in China. Biotage will provide systems and consumables within its Analytical Chemistry portfolio to be sold by Yingsheng under its own brand and together with Yingsheng’s other products and technical solutions.
“This collaboration opens up a market not previously available to Biotage and we believe that Biotage together with Yingsheng have good opportunities to be successful in this market environment. Clinical MS detection can be used in varied applications like Vitamin, Hormone and New Born screening. MS detection owns clear advantages in sensitivity and accuracy compared to traditional methods. Due to cost, complexity and technical reasons, it was not widely available before. This new joint effort is to provide a complete solution for this market from instrument, consumable to technical solution. For Biotage particularly it is also a great possibility to strengthen our efforts in China within Analytical Chemistry. Biotage has been very successful with its product offering in Organic Chemistry over the years and we are now looking very much forward to accelerate the Analytical Chemistry activities.” says Torben Jörgensen, CEO & President Biotage.